Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.

Granqvist M, Burman J, Gunnarsson M, Lycke J, Nilsson P, Olsson T, Sundström P, Svenningsson A, Vrethem M, Frisell T, Piehl F.

Mult Scler. 2019 Aug 8:1352458519866600. doi: 10.1177/1352458519866600. [Epub ahead of print]

PMID:
31392923
2.

Incidence of osmotic demyelination syndrome in Sweden: A nationwide study.

Aegisdottir H, Cooray C, Wirdefeldt K, Piehl F, Sveinsson O.

Acta Neurol Scand. 2019 Jul 25. doi: 10.1111/ane.13150. [Epub ahead of print]

PMID:
31343728
3.

GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis.

Galli E, Hartmann FJ, Schreiner B, Ingelfinger F, Arvaniti E, Diebold M, Mrdjen D, van der Meer F, Krieg C, Nimer FA, Sanderson N, Stadelmann C, Khademi M, Piehl F, Claassen M, Derfuss T, Olsson T, Becher B.

Nat Med. 2019 Aug;25(8):1290-1300. doi: 10.1038/s41591-019-0521-4. Epub 2019 Jul 22.

PMID:
31332391
4.

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.

Carlström KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, Checa A, Badam TVS, Huang J, Gomez-Cabrero D, Gustafsson M, Al Nimer F, Wheelock CE, Kockum I, Olsson T, Jagodic M, Piehl F.

Nat Commun. 2019 Jul 12;10(1):3081. doi: 10.1038/s41467-019-11139-3.

5.

Rituximab treatment for multiple sclerosis.

Ineichen BV, Moridi T, Granberg T, Piehl F.

Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604. [Epub ahead of print]

PMID:
31237800
6.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
7.

Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis.

Kular L, Needhamsen M, Adzemovic MZ, Kramarova T, Gomez-Cabrero D, Ewing E, Piket E, Tegnér J, Beck S, Piehl F, Brundin L, Jagodic M.

Clin Epigenetics. 2019 May 30;11(1):86. doi: 10.1186/s13148-019-0678-1.

8.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
9.

A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury.

Thelin E, Al Nimer F, Frostell A, Zetterberg H, Blennow K, Nyström H, Svensson M, Bellander BM, Piehl F, Nelson DW.

J Neurotrauma. 2019 Jun 19. doi: 10.1089/neu.2019.6375. [Epub ahead of print]

PMID:
31072225
10.

Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression.

Ewing E, Kular L, Fernandes SJ, Karathanasis N, Lagani V, Ruhrmann S, Tsamardinos I, Tegner J, Piehl F, Gomez-Cabrero D, Jagodic M.

EBioMedicine. 2019 May;43:411-423. doi: 10.1016/j.ebiom.2019.04.042. Epub 2019 Apr 30.

11.

Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury.

Minta K, Cullen NC, Nimer FA, Thelin EP, Piehl F, Clarin M, Tullberg M, Jeppsson A, Portelius E, Zetterberg H, Blennow K, Andreasson U.

Clin Chem Lab Med. 2019 Apr 15. pii: /j/cclm.ahead-of-print/cclm-2019-0034/cclm-2019-0034.xml. doi: 10.1515/cclm-2019-0034. [Epub ahead of print]

PMID:
30980710
12.

Morvan's syndrome treated successfully with rituximab and lacosamide.

Sveinsson O, Al Nimer F, Piehl F.

BMJ Case Rep. 2019 Feb 13;12(2). pii: e226832. doi: 10.1136/bcr-2018-226832.

PMID:
30765442
13.

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J.

Eur J Neurol. 2019 Aug;26(8):1060-1067. doi: 10.1111/ene.13936. Epub 2019 Mar 12.

PMID:
30762259
14.

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group.

Epidemiology. 2019 Mar;30(2):230-233. doi: 10.1097/EDE.0000000000000948.

15.

Increased peripheral levels of TARC/CCL17 in first episode psychosis patients.

Malmqvist A, Schwieler L, Orhan F, Fatouros-Bergman H, Bauer M, Flyckt L, Cervenka S, Engberg G, Piehl F; Karolinska Schizophrenia Project (KaSP) consortium, Erhardt S.

Schizophr Res. 2019 Aug;210:221-227. doi: 10.1016/j.schres.2018.12.033. Epub 2019 Jan 3.

PMID:
30612841
16.

B cell alterations during BAFF inhibition with belimumab in SLE.

Ramsköld D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mikeš J, Achour A, Amara K, Piehl F, Brodin P, Gunnarsson I, Malmström V.

EBioMedicine. 2019 Feb;40:517-527. doi: 10.1016/j.ebiom.2018.12.035. Epub 2018 Dec 26.

17.

Author Correction: Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 22;4(1):49. doi: 10.1038/s41572-018-0050-3.

PMID:
30467372
18.

Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Review. Erratum in: Nat Rev Dis Primers. 2018 Nov 22;4(1):49.

PMID:
30410033
19.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
20.

The association between multiple sclerosis and pain medications.

Burkill S, Montgomery S, Kockum I, Piehl F, Strid P, Hillert J, Alfredsson L, Olsson T, Bahmanyar S.

Pain. 2019 Feb;160(2):424-432. doi: 10.1097/j.pain.0000000000001429. Erratum in: Pain. 2019 Apr;160(4):986.

PMID:
30376533
21.

miR-31 regulates energy metabolism and is suppressed in T cells from patients with Sjögren's syndrome.

Johansson A, Nyberg WA, Sjöstrand M, Moruzzi N, Bergman P, Khademi M, Andersson M, Piehl F, Berggren PO, Covacu R, Jagodic M, Espinosa A.

Eur J Immunol. 2019 Feb;49(2):313-322. doi: 10.1002/eji.201747416. Epub 2018 Oct 22.

PMID:
30307034
22.

Identification of MS-specific serum miRNAs in an international multicenter study.

Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. doi: 10.1212/NXI.0000000000000491. eCollection 2018 Sep.

23.

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.

24.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
25.

Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis.

Orhan F, Schwieler L, Fatouros-Bergman H, Malmqvist A, Cervenka S, Collste K, Flyckt L, Farde L, Sellgren CM, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Engberg G, Erhardt S.

Acta Psychiatr Scand. 2018 Nov;138(5):432-440. doi: 10.1111/acps.12944. Epub 2018 Aug 21.

PMID:
30132802
26.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

27.

Polygenic link between blood lipids and amyotrophic lateral sclerosis.

Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F.

Neurobiol Aging. 2018 Jul;67:202.e1-202.e6. doi: 10.1016/j.neurobiolaging.2018.03.022. Epub 2018 Mar 27.

PMID:
29685649
28.

Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients.

Checa A, Malmqvist A, Flyckt L, Schwieler L, Samuelsson M, Skogh E, Cervenka S, Dahl ML, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Erhardt S, Wheelock CE.

Schizophr Res. 2018 Sep;199:438-441. doi: 10.1016/j.schres.2018.03.029. Epub 2018 Apr 4. No abstract available.

PMID:
29627172
29.

Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures.

Günther M, Al Nimer F, Piehl F, Risling M, Mathiesen T.

eNeuro. 2018 Mar 19;5(2). pii: ENEURO.0335-17.2018. doi: 10.1523/ENEURO.0335-17.2018. eCollection 2018 Mar-Apr.

30.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.

Piehl F, Hillert J.

Mult Scler. 2018 Aug;24(9):1157-1159. doi: 10.1177/1352458518757930. Epub 2018 Feb 22. No abstract available.

PMID:
29468952
31.

The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.

Eriksson I, Komen J, Piehl F, Malmström RE, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2018 May;74(5):663-670. doi: 10.1007/s00228-018-2429-1. Epub 2018 Feb 10.

32.

The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis.

Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, Kockum IS, Brundin L, Zahavi O, Wahlberg-Ramsay M, Brautaset R, Nilsson M.

Front Neurol. 2017 Dec 13;8:675. doi: 10.3389/fneur.2017.00675. eCollection 2017.

33.

Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients.

James T, Lindén M, Morikawa H, Fernandes SJ, Ruhrmann S, Huss M, Brandi M, Piehl F, Jagodic M, Tegnér J, Khademi M, Olsson T, Gomez-Cabrero D, Kockum I.

Hum Mol Genet. 2018 Mar 1;27(5):912-928. doi: 10.1093/hmg/ddy001.

PMID:
29325110
34.

Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers.

Brenner P, Granqvist M, Königsson J, Al Nimer F, Piehl F, Jokinen J.

Psychoneuroendocrinology. 2018 Mar;89:53-58. doi: 10.1016/j.psyneuen.2018.01.002. Epub 2018 Jan 4.

PMID:
29324301
35.

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F.

JAMA Neurol. 2018 Mar 1;75(3):320-327. doi: 10.1001/jamaneurol.2017.4011.

36.

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study.

Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2018 Feb;74(2):219-226. doi: 10.1007/s00228-017-2366-4. Epub 2017 Nov 11.

37.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmeström C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J.

Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

38.

Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis.

Varade J, Wang N, Lim CK, Zhang T, Zhang Y, Liu X, Piehl F, Matell R, Cao H, Xu X, Hammarström L.

J Autoimmun. 2018 Mar;88:43-49. doi: 10.1016/j.jaut.2017.10.002. Epub 2017 Oct 14.

PMID:
29037440
39.

Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.

Sveinsson O, Granqvist M, Forslin Y, Blennow K, Zetterberg H, Piehl F.

J Neuroimmunol. 2017 Nov 15;312:15-18. doi: 10.1016/j.jneuroim.2017.08.011. Epub 2017 Aug 25.

PMID:
28886955
40.

Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.

Ruhrmann S, Ewing E, Piket E, Kular L, Cetrulo Lorenzi JC, Fernandes SJ, Morikawa H, Aeinehband S, Sayols-Baixeras S, Aslibekyan S, Absher DM, Arnett DK, Tegner J, Gomez-Cabrero D, Piehl F, Jagodic M.

Mult Scler. 2018 Sep;24(10):1288-1300. doi: 10.1177/1352458517721356. Epub 2017 Aug 2.

41.

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.

Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A.

Mult Scler. 2018 Aug;24(9):1224-1233. doi: 10.1177/1352458517720044. Epub 2017 Aug 1.

PMID:
28762877
42.

Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis.

Longinetti E, Mariosa D, Larsson H, Ye W, Ingre C, Almqvist C, Lichtenstein P, Piehl F, Fang F.

Neurology. 2017 Aug 8;89(6):578-585. doi: 10.1212/WNL.0000000000004179. Epub 2017 Jul 12.

43.

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.

Spelman T, Frisell T, Piehl F, Hillert J.

Mult Scler. 2018 Jul;24(8):1087-1095. doi: 10.1177/1352458517713668. Epub 2017 Jun 26.

PMID:
28649912
44.

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.

Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, Olsson T.

Mult Scler. 2018 Jul;24(8):1046-1054. doi: 10.1177/1352458517715132. Epub 2017 Jun 19.

PMID:
28627962
45.

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis.

Simonsen CS, Hansen G, Piehl F, Edland A.

Mult Scler J Exp Transl Clin. 2016 Jul 12;2:2055217316658304. doi: 10.1177/2055217316658304. eCollection 2016 Jan-Dec.

46.

Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.

Jonsson DI, Pirskanen R, Piehl F.

Neuromuscul Disord. 2017 Jun;27(6):565-568. doi: 10.1016/j.nmd.2017.03.007. Epub 2017 Mar 16.

PMID:
28433474
47.

A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis.

Kannan V, Kiani NA, Piehl F, Tegner J.

Math Biosci. 2017 Jul;289:1-8. doi: 10.1016/j.mbs.2017.03.006. Epub 2017 Mar 29.

48.

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

Leurs CE, Podlesniy P, Trullas R, Balk L, Steenwijk MD, Malekzadeh A, Piehl F, Uitdehaag BM, Killestein J, van Horssen J, Teunissen CE.

Mult Scler. 2018 Apr;24(4):472-480. doi: 10.1177/1352458517699874. Epub 2017 Mar 15.

49.

CSF GABA is reduced in first-episode psychosis and associates to symptom severity.

Orhan F, Fatouros-Bergman H, Goiny M, Malmqvist A, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Cervenka S, Collste K, Victorsson P, Sellgren CM, Flyckt L, Erhardt S, Engberg G.

Mol Psychiatry. 2018 May;23(5):1244-1250. doi: 10.1038/mp.2017.25. Epub 2017 Mar 14.

50.

Population-based incidence and clinical characteristics of idiopathic intracranial hypertension.

Sundholm A, Burkill S, Sveinsson O, Piehl F, Bahmanyar S, Nilsson Remahl AIM.

Acta Neurol Scand. 2017 Nov;136(5):427-433. doi: 10.1111/ane.12742. Epub 2017 Feb 28.

PMID:
28244170

Supplemental Content

Support Center